AstraZeneca Reports Results of Calquence (acalabrutinib) in CALAVI Study for Hospitalized COVID-19 Patients
Shots:
- The CALAVI program involves assessing of Calquence + BSC vs BSC as monothx. in patients hospitalized with respiratory complications of COVID-19- but not on assisted ventilation. The studies are being conducted in the US and outside the US including the EU- Japan and South America
- The drug demonstrated the clinical improvement in peer-reviewed case series of 19 hospitalized patients with COVID-19 and hypoxia and/or inflammation. Results were published in Science Immunology
- Calquence is a BTK inhibitor- act by inhibiting its activity and has received the US FDA approval for hematological malignancies
Click here to read full press release/ article
Ref: AstraZeneca | Image: Twitter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com